COLLEGE PARK, Md. - A panel of federal advisers Wednesday supported approval of Theravance Inc.'s injectable antibiotic telavancin, despite the potential for the drug to cause birth defects and kidney problems. (BioWorld Today)

WASHINGTON — With the Democrats taking the White House and making big gains in both the House and Senate Tuesday, congressional oversight of medical product safety will shift from the FDA to industry, and device and drug makers should be prepared to be in the crosshairs, said John Manthei, global co-chair of the healthcare and life sciences practice at the Washington law firm Latham & Watkins. (Medical Device Daily)